Novartis AG

Novartis AG

NVS
Novartis AGUS flagNew York Stock Exchange
120.77
USD
+2.70
(+2.29%)
6.38EPS
18.93P/E
238.53BMarket Cap
Jul 17Next Earn
Capital Structure

in mil. unless spec.
Working Capital

in mil. unless spec.
Growth Rates

in mil. unless spec.
Quarterly Revenue

in mil. unless spec.
Quarterly Earnings Per Share

in mil. unless spec.
Quarterly Dividends Per Share

in mil. unless spec.

Company Description

CEO
Dr. Vasant Narasimhan M.D.
Full Time Employees
75,883
Sector
Healthcare
Industry
Drug Manufacturers - General
Address
Lichtstrasse 35 Basel Switzerland 4056
IPO Date
Nov 7, 1996
Similar Companies
Business
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Company News

  • Novartis Fabhalta® shows statistically significant and clinically meaningful improvements in hemoglobin in new population of patients with PNH

  • Top Cancer Stocks to Supercharge Your 2025 Portfolio

  • Why Novartis (NVS) is a Top Momentum Stock for the Long-Term

  • Novartis (NVS) Could Be a Great Choice

  • 2 Dividend Growth Stocks to Buy and Hold Forever

  • Novartis' Pluvicto shown to slow prostate cancer in earlier setting

  • Novartis's Cancer Treatment Pluvicto Shows Positive Results in Trial

  • Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer

  • Buy These 5 Low-Leverage Stocks Amid Volatile Market Sentiment

  • Novartis announces commencement of tender offer to acquire Regulus Therapeutics

  • Are You Looking for a High-Growth Dividend Stock?

  • If I Could Only Buy 2 Dividend Stocks Right Now (May 2025 Edition)

  • Here's Why Novartis (NVS) is a Strong Value Stock

  • Novartis (NVS) Upgraded to Buy: What Does It Mean for the Stock?

  • Should Value Investors Buy Novartis (NVS) Stock?

  • New Novartis data at ASCO and EHA showcase momentum of pioneering portfolio with promising pipeline

  • Dr. Scott Gottlieb: What to expect from President Trump's executive order to lower drug prices

  • Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet

  • Novartis to keep making malaria drugs if orders dry up amid aid cuts

  • Here's Why Novartis (NVS) is a Strong Momentum Stock